- HemoShear Therapeutics, Inc., a Charlottesville, Va.-based clinical stage company developing treatments for rare metabolic disorders, has raised $40m in Series A financing
- The round led by Suvretta Capital with participation from Janus Henderson Investors, Adage Capital Management LP and other private investors
- In conjunction with the financing, David Friedman, MD, Managing Director at Suvretta Capital and John Tilton will also join the board of HemoShear
- HemoShear is a clinical stage company developing treatments for rare metabolic disorders with significant unmet patient need
- The company also intends to use the funds to complete a phase 2 study of its lead compound, HST5040, an investigational oral small molecule therapy
- The FDA has granted the company’s HST5040 Orphan Drug, Fast Track and Rare Pediatric Disease designations to treat MMA and PA
